scholarly journals Potential effects of incretin-based therapies on polycystic ovary syndrome in rats: a comparative study of linagliptin versus liraglutide

2021 ◽  
Vol 12 (2) ◽  
pp. 1044-1054
Author(s):  
Hanan Abdelmoneam Shamardl ◽  
Hala Fawzy Kamel ◽  
Asmaa Mohamed Elsayed ◽  
Hiba Saeed Al-Amodi ◽  
Sahar Mohy El-Ashmony
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Antioxidant Activities ◽  
Polycystic Ovary ◽  
Combined Therapy ◽  
Therapeutic Effects ◽  
Metabolic Dysfunction ◽  
Ovary Syndrome ◽  
Tnf Α ◽  
Histological Improvement ◽  
Combined Drugs

Low glucagon like peptide1 (GLP-1) level may contribute to the metabolic dysfunction in polycystic ovary syndrome (PCOS).  In this study, prospective therapeutic effects of incretin-based drugs; linagliptin versus liraglutide were investigated on letrozole induced PCOS rats. Animals were divided into five groups (control, PCOS, linagliptin, liraglutide and combined). Letrozole was administered for seven weeks (1mg/kg/day,orally). Linagliptin (3mg/kg/day,orally), liraglutide (1.2mg/kg/day,sc) and combined drugs were given for 4 weeks. Measurements of anthropometric, hemodynamics, blood glucose indices, HOMA-IR, serum lipids, TNF-α, NF-kB, and sex hormones were estimated. Antioxidant activities alongside immunohistochemical (PCNA) studies were assessed. The present results proved that both drugs significantly ameliorated most of anthropometric, glycemic, lipid, hormonal, inflammatory and antioxidant indices. Obvious histological improvement was obtained by linagliptin and combined therapy while being questionable by liraglutide . In conclusion, linagliptin caused evident ovarian histological advance rather than liraglutide. Linagliptin may represent a promise in alleviating metabolic, hormonal and unique beneficial histologic effects of PCOS.

scholarly journals Berberine Phospholipid Is an Effective Insulin Sensitizer and Improves Metabolic and Hormonal Disorders in Women with Polycystic Ovary Syndrome: A One-Group Pretest–Post-Test Explanatory Study

Nutrients ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 3665
Author(s):  
Mariangela Rondanelli ◽  
Antonella Riva ◽  
Giovanna Petrangolini ◽  
Pietro Allegrini ◽  
Attilio Giacosa ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Sex Hormone ◽  
Model Assessment ◽  
Ovary Syndrome ◽  
Insulin Sensitizer ◽  
Tnf Α ◽  
Post Test ◽  
Liver And Kidney ◽  
Kidney Functions

Polycystic Ovary Syndrome (PCOS) is the most frequent endocrine disease in females of reproductive age and is characterized by multifactorial unhealthy conditions related to hormonal unbalance and also to dysmetabolism and inflammation. Recently, increasing evidence has shown that natural plant-based products may play a role in PCOS management. The aim of this one-group pretest–post-test explanatory study was to evaluate, in normal–overweight PCOS women with normal menses, the effectiveness of berberine on: Insulin resistance (IR) by Homeostasis Model Assessment (HOMA); Inflammation by C-Reactive Protein (CRP), Tumor Necrosis Factor α (TNF-α); Lipid metabolism; Sex hormone profile and symptoms correlated to hyperandrogenism, such as acne, by Global Acne Grading System (GAGS) and Cardiff Acne Disability Index (CADI); Body composition by DXA. Finally, adverse effects were assessed by liver and kidney functions and creatine phosphokinase (CPK). All these parameters were collected at baseline and 60 days after supplementation with a new bioavailable and safe berberine formulation. Twelve females (aged 26.6 ± 4.9, BMI 25.3 ± 3.6) were supplied for 60 days with two tablets/day (550 mg/table) of the bioavailable berberine. Results showed a statistically significant decrease in HOMA, CRP, TNF-α, Triglycerides, testosterone, Body Mass Index (BMI), Visceral Adipose Tissue (VAT), fat mass, GAGS and CADI scores, and a statistically significant increase in sex hormone-binding globulin (SHBG). Liver and kidney functions and CPK are not statistically significantly different. Therefore, berberine can represent a safe novel dietary supplement, helpful in treatment strategy for PCOS.

Therapeutic Effects of Biguanide Vs. Statin in Polycystic Ovary Syndrome: A Randomized Clinical Trial

2011 ◽  
Vol 14 (11) ◽  
pp. 658-663 ◽  
Author(s):  
Nazli Navali ◽  
Shabnam Pourabolgh ◽  
Rohollah Fadaei Fouladi ◽  
Mehri Amiri Nikpour
Keyword(s):  
Clinical Trial ◽  
Polycystic Ovary Syndrome ◽  
Randomized Clinical Trial ◽  
Polycystic Ovary ◽  
Therapeutic Effects ◽  
Ovary Syndrome

scholarly journals Animal Models to Understand the Etiology and Pathophysiology of Polycystic Ovary Syndrome

2020 ◽  
Vol 41 (4) ◽  
pp. 538-576 ◽  
Author(s):  
Elisabet Stener-Victorin ◽  
Vasantha Padmanabhan ◽  
Kirsty A Walters ◽  
Rebecca E Campbell ◽  
Anna Benrick ◽  
...  
Keyword(s):  
Animal Models ◽  
Polycystic Ovary Syndrome ◽  
Genetic Manipulation ◽  
Polycystic Ovary ◽  
Developmental Origins ◽  
Metabolic Dysfunction ◽  
Ovary Syndrome ◽  
Naturally Occurring ◽  
High Prevalence

Abstract More than 1 out of 10 women worldwide are diagnosed with polycystic ovary syndrome (PCOS), the leading cause of female reproductive and metabolic dysfunction. Despite its high prevalence, PCOS and its accompanying morbidities are likely underdiagnosed, averaging > 2 years and 3 physicians before women are diagnosed. Although it has been intensively researched, the underlying cause(s) of PCOS have yet to be defined. In order to understand PCOS pathophysiology, its developmental origins, and how to predict and prevent PCOS onset, there is an urgent need for safe and effective markers and treatments. In this review, we detail which animal models are more suitable for contributing to our understanding of the etiology and pathophysiology of PCOS. We summarize and highlight advantages and limitations of hormonal or genetic manipulation of animal models, as well as of naturally occurring PCOS-like females.

scholarly journals Metabolic dysfunction in obese Hispanic women with polycystic ovary syndrome

2015 ◽  
Vol 30 (6) ◽  
pp. 1358-1364 ◽  
Author(s):  
S. Sam ◽  
B. Scoccia ◽  
S. Yalamanchi ◽  
T. Mazzone
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Hispanic Women ◽  
Metabolic Dysfunction ◽  
Ovary Syndrome

scholarly journals Polycystic ovary syndrome: reviewing diagnosis and management of metabolic disturbances

2014 ◽  
Vol 58 (2) ◽  
pp. 182-187 ◽  
Author(s):  
Poli Mara Spritzer
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Diagnostic Criteria ◽  
Polycystic Ovary ◽  
Pharmacological Therapy ◽  
Lifestyle Changes ◽  
Reproductive Age ◽  
Metabolic Dysfunction ◽  
Metabolic Disturbances ◽  
Ovary Syndrome ◽  
Individual Woman

Polycystic ovary syndrome (PCOS) is a common condition in women at reproductive age associated with reproductive and metabolic dysfunction. Proposed diagnosed criteria for PCOS include two out of three features: androgen excess, menstrual irregularity, and polycystic ovary appearance on ultrasound (PCO), after other causes of hyperandrogenism and dysovulation are excluded. Based on these diagnostic criteria, the most common phenotypes are the “classic PCOS” – hyperandrogenism and oligomenorrhea, with or without PCO; the “ovulatory phenotype” – hyperandrogenism and PCO in ovulatory women; and the “non-hyperandrogenic phenotype”, in which there is oligomenorrhea and PCO, without overt hyperandrogenism. The presence of obesity may exacerbate the metabolic and reproductive disorders associated with the syndrome. In addition, PCOS women present higher risk for type 2 diabetes and higher prevalence of cardiovascular risk factors that seems to be associated with the classic phenotype. The main interventions to minimize cardiovascular and metabolic risks in PCOS are lifestyle changes, pharmacological therapy, and bariatric surgery. Treatment with metformin has been shown to improve insulin sensitivity, lowering blood glucose and androgen levels. These effects are more potent when combined with lifestyle interventions. In conclusion, besides reproductive abnormalities, PCOS has been associated to metabolic comorbidities, most of them linked to obesity. Confounders, such as the lack of standard diagnostic criteria, heterogeneity of the clinical presentation, and presence of obesity, make management of PCOS difficult. Therefore, the approach to metabolic abnormalities should be tailored to the risks and treatment goals of each individual woman.

Sign in / Sign up

Export Citation Format

Share Document